Skip to main content
. 2021 Mar 19;24:462–476. doi: 10.1016/j.omtn.2021.03.013

Figure 2.

Figure 2

Intracellular delivery of siRNAs in complex with 599 or its peptide variants

(A) Quantitative siRNA uptake into CAL 27 cancer cells 2 h post-treatment with DY547-siCIP2A in complex with 599 or its peptide variants at either the 30:1 or 50:1 Peptide:siRNA molar (7.5 or 12.5 N/P) ratios. For comparison, the cells were also transfected using the commercial lipid-based transfection reagent (LTR), Lipofectamine 3000 (LF3000). The amount of siRNA delivered into cells in pmol per mg of protein is reported with each treatment normalized to DY547-siCIP2A alone. Data are mean ± SEM of three independent samples, where ∗p < 0.05, ∗∗p < 0.01, and p ≥ 0.05 is not significant (ns) compared to 599 (2-way ANOVA). (B) Confocal fluorescence microscopy analysis of CAL 27 cancer cells 2 h post-treatment with DY547-CIP2A (red) in complex with 599 or its peptide variants at 50:1 Peptide:siRNA molar (12.5 N/P) ratios. Nuclei (blue) were counterstained with DAPI. The arrowheads indicate highly ordered linear punctate uptake patterns of siRNAs in the RD3AD panel. Scale bar: 35 μm.